The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Surface Protein gp120 - Drugs in Development, 2021
US$ 3,000.00
Surface Protein gp120 - Drugs in Development, 2021 SUMMARY Surface Protein gp120 - Drugs in Development, 2021 provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics. The re...
April 2021
70 pages
T-Cell Leukemia (Oncology) - Drugs in Development, 2021
US$ 2,000.00
T-Cell Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY T-Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the T-Cell Leukemia pipeline landscape. The report provi...
April 2021
80 pages
T-Cell Lymphomas (Oncology) - Drugs in Development, 2021
US$ 2,000.00
T-Cell Lymphomas (Oncology) - Drugs in Development, 2021 SUMMARY T-Cell Lymphomas (Oncology) - Drugs in Development, 2021 provides an overview of the T-Cell Lymphomas pipeline landscape. The report pr...
April 2021
125 pages
Testicular Cancer (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Testicular Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Testicular Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Testicular Cancer pipeline landscape. The report...
April 2021
40 pages
Thrombosis (Cardiovascular) - Drugs in Development, 2021
US$ 2,000.00
Thrombosis (Cardiovascular) - Drugs in Development, 2021 SUMMARY Thrombosis (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Thrombosis pipeline landscape. The report provides...
April 2021
105 pages
Thymic Carcinoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Thymic Carcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Thymic Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Thymic Carcinoma pipeline landscape. The report pr...
April 2021
75 pages
Transferrin Receptor (TFR) - Drugs in Development, 2021
US$ 3,000.00
Transferrin Receptor (TFR) - Drugs in Development, 2021 SUMMARY Transferrin Receptor (TFR) - Drugs in Development, 2021 provides in depth analysis on Transferrin Receptor (TFR) targeted pipeline thera...
April 2021
35 pages
